Welcure Drugs & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 524661 | NSE: | Trading | Small Cap

Welcure Drugs&Pharma Share Price

3.76 -0.19 -4.81%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Welcure Drugs&Pharma

M-Cap below 100cr DeciZen not available

Welcure Drugs & Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
461.87
Market Cap:
5.1 Cr.
52-wk low:
3.2
52-wk high:
5.5

Is Welcure Drugs & Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Welcure Drugs & Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Welcure Drugs & Pharmaceuticals Ltd is a average quality company.

2. Is Welcure Drugs & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Welcure Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Welcure Drugs & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Welcure Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Welcure Drugs&Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Welcure Drugs & Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -3.7%-7.7%-274.5%108.8%-65.6%18.1%-49.1%131.9%29.1%11.4%-
Value Creation
Index
-1.3-1.6-20.66.8-5.70.3-4.58.41.1-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00.10.10.10.10.10.10.10.100
Sales YoY Gr.-25%100%-10%-44.4%60%0%62.5%-15.4%-100%-
Adj EPS 000.10-00-0000.10
YoY Gr.-NANA-66.7%-150%NANANA-50%250%-
BVPS (₹) -0.1-0.1000000.10.11.11.1
Adj Net
Profit
000.100000.100.10
Cash Flow from Ops. 00-0.10000000.1-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -100%-100%-100%-100%
Adj EPS NANANA250%
BVPSNA124.1%383.5%1312.5%
Share Price 12.2% 48% 24.7% -7.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-3.6-7.6-274.3108.6-65.817.8-49.5131.72911.30.9
Op. Profit
Mgn %
-27.16.932.430.9-412.9-11.641.322.50NAN
Net Profit
Mgn %
7.811.685.630.8-38.84.9-11.441.422.50INF
Debt to
Equity
0000000000-
Working Cap
Days
534528601095976619800
Cash Conv.
Cycle
00000000000

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 0.90%

Sales growth has been subdued in last 3 years -100.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Welcure Drugs & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 0 -1.3
TTM Sales (₹ Cr.) 0 0.4
BVPS (₹.) 1.1 0
Reserves (₹ Cr.) -12 -13
P/BV 3.55 0.00
PE 461.87 0.00
From the Market
52 Week Low / High (₹) 3.20 / 5.48
All Time Low / High (₹) 0.36 / 40.00
Market Cap (₹ Cr.) 5.1
Equity (₹ Cr.) 13.5
Face Value (₹) 10
Industry PE 76.7

Management X-Ray of Welcure Drugs&Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Welcure Drugs&Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales0.040.050.100.090.050.080.080.130.110
Operating Expenses 0.050.050.070.060.070.080.090.080.080.13
Manufacturing Costs0000000000
Material Costs0000000000
Employee Cost 0000000000.03
Other Costs 0.050.050.070.060.070.080.090.080.080.10
Operating Profit -0.0100.030.03-0.020-0.010.060.02-0.13
Operating Profit Margin (%) -27.1%6.9%32.4%30.9%-41.0%2.9%-11.6%41.3%22.5%-
Other Income 0.0100.050000000.24
Interest 0000000000
Depreciation 0000000000
Exceptional Items 0000000000
Profit Before Tax 00.010.090.03-0.020-0.010.060.020.10
Tax 0000000000
Profit After Tax 00.010.090.03-0.020-0.010.060.020.10
PAT Margin (%) 7.8%11.6%85.6%30.8%-38.8%4.9%-11.4%41.4%22.5%-
Adjusted EPS (₹)0.00.00.10.00.00.00.00.10.00.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund -0.08-0.070.010.040.020.020.010.070.091.52
Share Capital 12.1212.1212.1212.1212.1212.1212.1212.1212.1213.44
Reserves -12.20-12.19-12.11-12.08-12.10-12.09-12.10-12.05-12.03-11.92
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables0000000000
Others Liabilities 0.130.130000.010.01000.01
Total Liabilities 0.050.060.020.040.020.030.020.070.101.53

Fixed Assets

Gross Block0000000000.06
Accumulated Depreciation0000000000
Net Fixed Assets0000000000.06
CWIP 0000000000
Investments 0000000000.17
Inventories0000000000
Trade Receivables0000000000
Cash Equivalents 0.050.050.010.020.010.010.010.050.070
Others Assets0.010.010.010.020.010.010.020.030.031.31
Total Assets 0.050.060.020.040.020.030.020.070.101.53

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 00.01-0.050.02-0.010-0.010.040.020.11
PBT 00.010.090.03-0.020-0.010.060.020.10
Adjustment 0000000000
Changes in Working Capital -00-0.13-0.010.01-0-0-0.01-0.010.01
Tax Paid 0000000000
Cash Flow From Investing Activity -0.0200.030000001.32
Capex 0000000000
Net Investments 0000000000
Others -0.0200.030000001.32
Cash Flow From Financing Activity 000000000-1.49
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000000
Dividend Paid 0000000000
Others 000000000-1.49
Net Cash Flow -0.030.01-0.020.02-0.010-0.010.040.02-0.06
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)N/AN/A0108.61-65.817.83-49.46131.7429.0312.65
ROCE (%)N/AN/A0108.91-65.4618.22-48.94131.9429.1212.67
Asset Turnover Ratio0.730.92.663.071.512.993.032.731.240
PAT to CFO Conversion(x)NAN1-0.560.67N/ANANN/A0.6711.1
Working Capital Days
Receivable Days0000000000
Inventory Days0000000000
Payable Days0000000000

Welcure Drugs & Pharmaceuticals Ltd Stock News

Welcure Drugs & Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Welcure Drugs&Pharma on 28-Mar-2024 16:01 is ₹3.76.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Welcure Drugs&Pharma stood at ₹5.08.
The latest P/E ratio of Welcure Drugs&Pharma as of 28-Mar-2024 16:01 is 461.9.
The latest P/B ratio of Welcure Drugs&Pharma as of 28-Mar-2024 16:01 is 3.55.
The 52-week high of Welcure Drugs&Pharma is ₹5.48 and the 52-week low is ₹3.20.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Welcure Drugs&Pharma is ₹0.00 ( Cr.) .

About Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.

Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups.  The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals.  The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.

In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).

The Company’s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.

Product range of the company includes:

Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:

  • Brucure
  • Diclo-plus, Dimcinplus
  • Nimesulide
  • Nimagyltd (tongue dissolvent)
  • Ibucure & Relaxon Forte
  • Coldrest, Alert10004 Coldhistex
  • Cezen & Cezen Forte, Cezen CD
  • Kuffwel
  • X-Dryl, X-Dryl Forte
  • Renact DM
  • Renact DC
  • Diaroban
  • Welcee (Chewable Tab.)
  • Calbiplex
  • Wormicide
  • X-Clox
  • Weloxy-L
  • Welquin
  • Nortin, Cipcin-TNZ
  • Sarvo
  • B-Rest
  • Lopcure
  • Rifampicin, Ethambutol, Rifa-Z
  • Weloxy-P,Amicure-P
  • Norkid
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.